Nour Kenaan

Dr. Nour Kenaan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Cancer Medicine
Verified
Journal Article
Open access
NKNour Kenaan
Nour Kenaan
GHGeorge Hanna
George Hanna
MSMoustafa Sardini
Moustafa Sardini
MIMhd Omar Iyoun
Mhd Omar Iyoun
KLKhedr Layka
Khedr Layka
ZAZuheir Alshehabi
Zuheir Alshehabi
Background: Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and increase survival rates.Aims: To define the most efficient and cost‐effective method of early detection in clinical practice.Materials and Methods: We collected the Information used to write this review by searching papers through PUBMED that were published from 2021 to 2024, mainly systematic reviews, meta‐analyses and clinical‐trials. We also included other older but notable papers that we found essential and valuable for understanding.Results: EB‐OCT has a varied sensitivity and specificity—an average of 94.3% and 89.9 for each. On the other hand, detecting biomarkers via liquid biopsy carries an average sensitivity of 91.4% for RNA molecules detection, and 97% for combined methylated DNA panels. Moreover, CTCs detection did not prove to have a significant role as a screening method due to the rarity of CTCs in the bloodstream thus the need for more blood samples and for enrichment techniques.Discussion: Although low‐dose CT scan (LDCT) is the current golden standard screening procedure, it is accompanied by a highly false positive rate. In comparison to other radiological screening methods, Endobronchial optical coherence tomography (EB‐OCT) has shown a noticeable advantage with a significant degree of accuracy in distinguishing between subtypes of non‐small cell lung cancer. Moreover, numerous biomarkers, including RNA molecules, circulating tumor cells, CTCs, and methylated DNA, have been studied in the literature. Many of these biomarkers have a specific high sensitivity and specificity, making them potential candidates for future early detection approaches.Conclusion: LDCT is still the golden standard and the only recommended screening procedure for its high sensitivity and specificity and proven cost‐effectiveness. Nevertheless, the notable false positive results acquired during the LDCT examination caused a presumed concern, which drives researchers to investigate better screening procedures and approaches, particularly with the rise of the AI era or by combining two methods in a well‐studied screening program like LDCT and liquid biopsy. we suggest conducting more clinical studies on larger populations with a clear demographical target and adopting approaches for combining one of these new methods with LDCT to decrease false‐positive cases in early detection.

1 January 2025 in AIMS Neuroscience
Verified
Journal Article
Open access
PDF file
NKNour Kenaan
Nour Kenaan
ZAZuheir Alshehabi
Zuheir Alshehabi
Alzheimer's Disease (AD) remains a significant global health challenge, characterized by progressive neurodegeneration and a decline in cognitive abilities such as memory and learning. Despite being the main cause of dementia worldwide, the precise mechanisms that underlie neuronal dysfunction and synaptic plasticity impairment in AD remain elusive. However, while genetic mutations, dietary factors, and immune dysregulation are implicated in AD pathogenesis, the current therapeutic approaches are largely centered around acetylcholinesterase inhibitors (AChEIs). Nevertheless, this cholinergic hypothesis of AD is no longer satisfactory in describing this disease and has demonstrated a limited efficacy. Hence, new treatment approaches should be developed, and that requires us to view AD from a new perspective. Herein, in our review, we present the latest studies that discussed possible AD pathologies and pharmacotherapies. Additionally, we highlight that the emerging treatments that precisely targets brain regions associated with enhancing neuroplasticity have delivered promising results and seem to be more effective than older treatments. Finally, by viewing AD as a complex interplay of various factors that ultimately cause synaptic dysfunction and cognitive decline, we can develop more effective therapeutic interventions and ultimately alleviate the significant burden of this debilitating disease for both patients and their families.

6 April 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MAMoatasem Ali Hussein Al-janabi
Moatasem Ali Hussein Al-janabi
NKNour Kenaan
Nour Kenaan
SSSara Houssam Sulaiman
Sara Houssam Sulaiman
JIJana Ahmad Ibrahim
Jana Ahmad Ibrahim
NSNour Abd Allatif Saoud
Nour Abd Allatif Saoud
RSRabab Salloum
Rabab Salloum
Introduction and importance: Ectopic liver tissue is an exceedingly rare anomaly in which the hepatic tissue is present extrahepatic site and has no connection to the true liver. Most cases of ectopic liver tissue were asymptomatic and discovered by an accident during abdominal surgery or autopsy. Case presentation: Case 1 involved a 52-year-old man who was admitted to the hospital due to an abdominal grip in the right hypochondrium and epigastrium for 1 month. The patient underwent laparoscopic cholecystectomy. During the gross examination, a well-circumscribed brownish nodule with a smooth outer surface, located at the fundus region was found. Case 2 involved a 40-year-old man with 2 months history of epigastric pain radiating to the right shoulder. Calculus chronic cholecystitis was diagnosed by ultrasound. The patient undergoes elective laparoscopic cholecystectomy. A gross inspection showed a small nodule attached to the serosa of the gallbladder. Microscopically, both cases revealed ectopic liver tissue. Clinical discussion: Ectopic liver tissue is an uncommon entity that occurs during the embryological development of the liver and can be found below and above the diaphragm, especially the gallbladder. Histologically, it usually has the normal architecture of the liver. Although ectopic liver tissue is an exceptional finding, pathologists should be aware of it because it has a high risk of transformation into malignancy. Conclusion: Hepatic choristoma is a rare failure of embryological liver development. It should be removed when recognized and examined histologically to rule out malignancy.

5 July 2026 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
NKNour Kenaan
Nour Kenaan
GBGeorge Bashour
George Bashour
NKNina Kheyrbek
Nina Kheyrbek
SHSaddik Haddad
Saddik Haddad
MSMoustafa Sardini
Moustafa Sardini
ZAZuheir Alshehabi
Zuheir Alshehabi
Background: Glioblastoma (GB), or grade IV astrocytoma, is the most prevalent primary tumor of the central nervous system (CNS). This systematic review aimed to investigate the efficacy and tolerability of virotherapy treatment for recurrent and progressive glioblastoma patients. We also examined recent progress in preclinical and clinical trials, and future perspectives. Methods: We developed a search strategy using Medical Subject Headings (MeSH) terms and keywords. Inclusion criteria were English language published and ongoing clinical trials that involved patients undergoing virotherapy for glioblastoma. We searched through PubMed, Embase, Ovid, Scopus, Cochrane databases and https://Clinicaltrials.gov from inception until May 9 th , 2025. Two independent reviewers screened records, extracted data, and assessed risk of bias (ROB2). No meta-analysis was performed due to heterogeneity. PROSPERO CRD420250636791. Results: Of 975 records screened, 43 studies (24 published, 19 ongoing) enrolled 462 virotherapy patients. Most common adverse events: headache (n=145), fatigue (n=83) and fever (n=78). Risk of bias was moderate to serious in most studies. Conclusion: We encountered several limitations, including high heterogeneity, reporting inconsistencies, and small sample sizes. Most patients experienced disease stabilization. However, objective response and complete remission occurred infrequently. A small proportion of patients achieved long-term survival, suggesting that virotherapy could be effective in specific subgroups. While oncolytic virus therapy is generally tolerated, neurotoxicity remains the most significant risk. Adverse effects were mostly Grade 1–2. Some trials (notably with HSV-1 or NDV) had severe events. Symptoms were often transient and manageable but need closely monitoring. However, the observed heterogeneity, limited data standardisation, and lack of randomized controlled trials, besides tumor heterogeneity, antiviral immunity and immunosuppressive microenvironment, necessitate further research to identify predictive biomarkers and optimize therapeutic protocols. We also suggest further trials on novel delivery methods, such as the nanoparticles, to enhance blood-brain barrier (BBB) penetration.

30 June 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
NKNour Kenaan
Nour Kenaan
MAMohammad Al Aboud
Mohammad Al Aboud
TJTala Jaber
Tala Jaber
SSSara Shaban
Sara Shaban
JDJad Daher
Jad Daher
ZAZuheir Alshehabi
Zuheir Alshehabi
Background: Acetylsalicylic acid (aspirin) is a widely used medication with antipyretic, anti-inflammatory, and antiplatelet effects. It also exhibits antitumor properties by enhancing immune responses, downregulating proinflammatory cytokines, and interfering with platelet–tumor cell interactions that promote metastatic dissemination. Identifying effective, safe interventions for brain metastases (BMs) remains a major clinical challenge. Objectives: This narrative review synthesizes mechanistic, preclinical, clinical, and safety evidence on aspirin's potential role in preventing or modulating brain metastasis and proposes possible preventive and adjuvant strategies for future investigation. Discussion: The development of BMs involves tumor-derived factors, extracellular vesicles, and recruited host cells that remodel the brain microenvironment into a premetastatic niche. Platelet activation and the COX-1/TXA 2 axis promote platelet–tumor cell aggregates, immune evasion, and endothelial adhesion—key steps in metastatic seeding. Aspirin may inhibit these processes by (1) irreversibly blocking platelet COX-1 (reducing TXA 2 and aggregation), (2) lowering prostaglandin E 2 (PGE 2 )–mediated immunosuppression, and (3) preserving blood–brain barrier (BBB) integrity. Preclinical and retrospective clinical studies provide supportive but heterogeneous evidence across cancer types. Combination strategies—aspirin with radiotherapy, antioxidants (e.g., ascorbic acid), or immunotherapy—are biologically plausible and supported by limited data. Major safety concerns remain, particularly bleeding risk and intracranial hemorrhage in patients with intracranial disease. Conclusion: Aspirin is a low-cost, biologically plausible adjunct for metastasis prevention. However, direct evidence in brain-metastasis settings is limited. Prospective trials with mechanistic biomarkers and careful safety monitoring are required to determine optimal dosing, timing, patient selection, and combination strategies.